ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address mechanisms of therapeutic resistance in cancer. Headquartered in South San Francisco, California, the company utilizes precision oncology to target innate, acquired, and bypass resistance in various tumors. Its clinical-stage pipeline includes rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) being developed for prostate cancer. The company is also advancing enozertinib (ORIC-114), a brain-penetrant inhibitor targeting specific EGFR mutations for non-small cell lung cancer, and ORIC-533, a CD73 inhibitor. By leveraging genetic analysis and tumor biology, ORIC aims to make existing cancer treatments more effective and prolong their clinical benefit for patients with hard-to-treat cancers.
